Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis
Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis Share Article Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020. BUDAPEST, Hungary (PRWEB) March 16, 2021 The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rhe...
Source: prweb.com